Autopsy report · NCT03879629

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

“slow accrual; insufficient funding to continue to accrue”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 years 6 months before it stopped.
• 224 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Carvedilol

Participants

224

Sites

5

Countries

United States

Trials that died the same way

• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
  “Slow accrual, Funding stopped” (91% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (91% match in meaning)
• Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
  “Slow accrual and lack of funding” (88% match in meaning)
• Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
  “Insufficient accrual and no funding” (82% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.